Proteomics International Laboratories has announced a national distribution agreement with Healius that will make the Promarker portfolio available across Australia through the Healius pathology network.

BLS Pharmaceuticals has entered a non-binding heads of agreement with Trexapharm to explore the Australian commercialisation of TREXAVIVE, a proprietary, patented neurotherapy being developed for treatment-resistant depression.

Telix Pharmaceuticals has reported robust commercial momentum in the quarter ended June 30, 2026, with group revenue of US$247 million, up 21 per cent year over year and 7 per cent from the prior quarter.

LTR Pharma has taken a major step toward its planned US commercial launch by executing a definitive agreement with Strive Specialties, converting a previously announced binding term sheet into a long-form commercial arrangement for the nationwide supply of its therapy in the United States.

Australian company Actinogen Medical has announced that results from its Phase 2 proof-of-concept trial of XANAMEM (emestedastat) have been published in the British Journal of Psychiatry, reporting meaningful antidepressant activity in a population described as difficult to treat.

Syntara Chief Executive Officer Gary Phillips said, “Completion of the first AZALOX cohort without any dose-limiting toxicities and clearance to progress to the 200 mg dose represents an important step forward for the amsulostat program."

PYC Therapeutics, a clinical-stage precision medicine company, has reported new data that strengthen the case for its lead drug candidate, PYC-001, as a potential disease-modifying treatment for Autosomal Dominant Optic Atrophy.

Telix Pharmaceuticals has opened a major facility in North Melbourne that brings radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging together under one roof.

Starpharma has launched a fully underwritten renounceable entitlement offer to raise approximately $32 million, strengthening its balance sheet and providing a pro forma cash balance of $44.5 million.

Clarity’s Executive Chairperson, Dr Alan Taylor, said, "We are very pleased to welcome Ali to the Board as an independent Non‑Executive Director."

Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa.

Algorae Pharmaceuticals has appointed Troy Valentine as a Non-Executive Director, a move the company says will materially deepen its board capability in capital markets, life sciences governance and international listed-company leadership. 

AusBiotech has announced a new partnership designed to provide its members with discounted access to Oktopi’s AI-informed platform and to expand the services available through the organisation's Business Solutions Program.

Patrys has struck a binding agreement with Yale that transfers ownership of the deoxymab intellectual property to the university while securing Patrys a 50 per cent share of any future commercialisation revenue directly attributable to the deoxymab portfolio.

CLINUVEL has announced that Health Canada has granted a Notice of Compliance allowing SCENESSE to be marketed in the country for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria, a rare metabolic disorder that causes debilitating phototoxic reactions and burns after brief exposure to visible light.

OncoSil Medical has completed three manufacturing validation cycles with partner Cyclotek, producing more than 50 validation doses of its OncoSil device and establishing a dedicated Australian manufacturing capability.

Immutep has reported mature overall survival data from the investigator‑initiated INSIGHT‑003 trial that it says offer a hopeful signal for eftilagimod alfa, known as efti, in first-line non‑squamous non‑small cell lung cancer.